BackgroundScreening at hospital admission for carriage of methicillin-resistant
Staphylococcus aureus (MRSA) has been proposed as a
strategy to reduce nosocomial infections. The objective of this study was to
determine the long-term costs and health benefits of selective and universal
screening for MRSA at hospital admission, using both PCR-based and
chromogenic media-based tests in various settings.Methodology/Principal FindingsA simulation model of MRSA transmission was used to determine costs and
effects over 15 years from a US healthcare perspective. We compared
admission screening together with isolation of identified carriers against a
baseline policy without screening or isolation. Strategies included
selective screening of high risk patients or universal admission screening,
with PCR-based or chromogenic media-based tests, in medium (5%) or
high nosocomial prevalence (15%) settings. The costs of screening and
isolation per averted MRSA infection were lowest using selective
chromogenic-based screening in high and medium prevalence settings, at
$4,100 and $10,300, respectively. Replacing the
chromogenic-based test with a PCR-based test costs $13,000 and
$36,200 per additional infection averted, and subsequent extension to
universal screening with PCR would cost $131,000 and $232,700
per additional infection averted, in high and medium prevalence settings
respectively. Assuming $17,645 benefit per infection averted, the
most cost-saving strategies in high and medium prevalence settings were
selective screening with PCR and selective screening with chromogenic,
respectively.Conclusions/SignificanceAdmission screening costs $4,100–$21,200 per infection
averted, depending on strategy and setting. Including financial benefits
from averted infections, screening could well be cost saving.